Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 2/20 | 0.31 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014116 | 0.75 | TRIM24 (0.50) | KMT2AALDH1A1POLBTRIM24TRIM33 | |
| SCHEMBL14596454 | 0.72 | CYP1A2 (0.41) | KMT2AALDH1A1CYP1A2CYP2C9LMNA | |
| SCHEMBL14364106 | 0.72 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP2C9LMNAMAPT | |
| SCHEMBL14364101 | 0.71 | PKM (0.37) | KMT2AALDH1A1CYP1A2CYP2C9LMNA | |
| SCHEMBL29042327 | 0.68 | MAPT (0.55) | KMT2AALDH1A1LMNAMAPTATM | |
| SCHEMBL6237426 | 0.67 | — | — | |
| SCHEMBL7048214 | 0.67 | SMN1; SMN2 (0.40) | KMT2AALDH1A1POLBCYP1A2CYP2C9 | |
| SCHEMBL868224 | 0.67 | MAPT (0.35) | ALDH1A1CYP1A2CYP2C9LMNAMAPT | |
| SCHEMBL7049450 | 0.67 | CYP1A2 (0.37) | ALDH1A1CYP1A2CYP2C9LMNAMAPT | |
| SCHEMBL8655214 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114384756-A | Resin composition, toner for developing electrostatic image, image forming method, photosensitive adhesive, and photoswitch material | 柯尼卡美能达株式会社 | 2022-04-22 | — | — | CN | disclosed |
| US-20040242591-A1 | Oxazolidinone derivatives as pontential antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-02 | — | — | US | disclosed |
| EP-0850224-B1 | RADIATION-ACTIVATED CYTOTOXIN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2003-04-09 | — | — | EP | disclosed |
| EP-1225169-A1 | Radiation-activated cytotoxin therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2002-07-24 | — | — | EP | disclosed |
| EP-1173414-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064864-A9 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000064864-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-11-02 | — | — | WO | disclosed |
| US-6071908-A | A RADIATION-ACTIVATED CYTOTOXIN PRODRUG HAVING LOW TOXICITY, WHICH CAN BE REDUCED BY REDUCING AGENTS GENERATED BY THE RADIOLYSIS OF WATER WHICH RELEASES AN CYTOXIC EFFECTOR; ANTITUMOR,-CARCINOGENIC AGENTS; | AUCKLAND UNISERVICES LIMITED (NZ) | 2000-06-06 | — | — | US | disclosed |
| EP-0850224-A1 | RADIATION-ACTIVATED CYTOTOXIN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997007101-A1 | RADIATION-ACTIVATED CYTOTOXIN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242591-A1 | Oxazolidinone derivatives as pontential antimicrobials | PDK4, OXA1L, PPARD | KMT2A 4151/4885ALDH1A1 1234/4885POLB 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.